Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes., Blood, 89, 2079, 10.1182/blood.V89.6.2079 Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making., J Clin Oncol, 23, 7594, 10.1200/JCO.2005.01.7038 Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes., J Clin Oncol, 25, 3503, 10.1200/JCO.2006.08.5696 Kantarjian, 2008, Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System., Cancer, 113, 1351, 10.1002/cncr.23697 Della Porta, 2011, Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome., Haematologica, 96, 441, 10.3324/haematol.2010.033506 Vardiman, 2009, The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia, rationale and important changes., Blood, 114, 937, 10.1182/blood-2009-03-209262 Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes., Br J Haematol, 51, 189, 10.1111/j.1365-2141.1982.tb08475.x Schanz, 2012, New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes and oligoblastic AML following MDS derived from an international database merge., J Clin Oncol, 30, 820, 10.1200/JCO.2011.35.6394 Wimazal, 2001, Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes., Leuk Res, 25, 287, 10.1016/S0145-2126(00)00140-5 Germing, 2005, Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes., Leukemia, 19, 2223, 10.1038/sj.leu.2403963 Wimazal, 2008, Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes., Ann Oncol, 19, 970, 10.1093/annonc/mdm595 Sanz, 2008, Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]., Blood, 112, 10.1182/blood.V112.11.640.640 Gatto, 2003, Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)., Blood, 102, 1622, 10.1182/blood-2002-10-3264 Neumann, 2009, Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia., Leuk Res, 33, 232, 10.1016/j.leukres.2008.06.003 Verburgh, 2003, Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes., J Clin Oncol, 21, 273, 10.1200/JCO.2003.04.182 Buesche, 2008, Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes., Leukemia, 22, 313, 10.1038/sj.leu.2405030 Della Porta, 2009, Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes., J Clin Oncol, 27, 754, 10.1200/JCO.2008.18.2246 Wang, 2009, Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes., Leuk Res, 33, 1594, 10.1016/j.leukres.2009.02.005 Naqvi, 2011, Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model., J Clin Oncol, 29, 2240, 10.1200/JCO.2010.31.3353 Pfeilstöcker, 2012, Time changes in predictive power of established and recently proposed clinical, cytogenetic and comorbidity scores for myelodysplastic syndromes., Leuk Res, 36, 132, 10.1016/j.leukres.2011.09.007 Shaffer, 2009, An International System for Human Cytogenetic Nomenclature: Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature Grambsch, 1995, Diagnostic plots to reveal functional form for covariates in multiplicative intensity models., Biometrics, 51, 1469, 10.2307/2533277 Minder, 1996, A robust method for proportional hazards regression., Stat Med, 15, 1033, 10.1002/(SICI)1097-0258(19960530)15:10<1033::AID-SIM215>3.0.CO;2-Y Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors., Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 R Development Core Team, R Foundation for Statistical Computing R: A Language and Environment for Statistical Computing [Internet]. 2009 Accessed March 1, 2012 http://www.r-project.org Therneau TM Lumley T Survival analysis, including penalized likelihood. Accessed March 1, 2012 http://www.r-project.org Kao, 2008, Impact of cytopenias on clinical outcomes in myelodysplastic syndrome., Am J Hematol, 83, 765, 10.1002/ajh.21249 Malcovati, 2011, Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)., Haematologica, 96, 1433, 10.3324/haematol.2011.044602 Sanz, 1989, Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients., Blood, 74, 395, 10.1182/blood.V74.1.395.395 Cordoba, 2012, The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome., Leuk Res, 36, 287, 10.1016/j.leukres.2011.10.025 Kantarjian, 2007, The incidence and impact of thrombocytopenia in myelodysplastic syndromes., Cancer, 109, 1705, 10.1002/cncr.22602 Aul, 1992, Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system., Leukemia, 6, 52 Gonzalez-Porras, 2011, Spanish Myelodysplastic Syndrome Registry: prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome., Cancer, 117, 5529, 10.1002/cncr.26173 Morel, 1996, Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques., Br J Haematol, 94, 116, 10.1046/j.1365-2141.1996.6122056.x Kuendgen, 2006, Myelodysplastic syndromes in patients younger than age 50., J Clin Oncol, 24, 5358, 10.1200/JCO.2006.07.5598 Nösslinger, 2010, Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes., Ann Oncol, 21, 120, 10.1093/annonc/mdp264 Stauder, 2008, Impact of age and comorbidity in myelodysplastic syndromes., J Natl Compr Canc Netw, 6, 927, 10.6004/jnccn.2008.0070 Zipperer, 2009, The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome., Haematologica, 94, 729, 10.3324/haematol.2008.002063 Sperr, 2010, Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core data set of 582 patients of the Austrian MDS Platform., Ann Oncol, 21, 114, 10.1093/annonc/mdp258 Park, 2011, Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS., Leuk Res, 35, 1530, 10.1016/j.leukres.2011.07.007 Deeg, 2000, Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome., Leuk Lymphoma, 37, 405, 10.3109/10428190009089441 Verma, 2005, Cytokine targets in the treatment of myelodysplastic syndromes., Curr Hematol Rep, 4, 429 Greenberg, 2011, NCCN Practice Guidelines for in Oncology: myelodysplastic syndromes., J Natl Compr Canc Netw, 9, 30, 10.6004/jnccn.2011.0005 Smith, 2003, Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series., Blood, 102, 43, 10.1182/blood-2002-11-3343 Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes., N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343 Papaemmanuil, 2011, Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts., N Engl J Med, 365, 1384, 10.1056/NEJMoa1103283 Walter, 2012, Clonal architecture of secondary acute myeloid leukemia., N Engl J Med, 366, 1090, 10.1056/NEJMoa1106968 van de Loosdrecht, 2008, Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry., Blood, 111, 1067, 10.1182/blood-2007-07-098764 Westers, 2012, Standardization of flow cytometry in myelodysplastic syndromes: a report from an International Consortium and the European LeukemiaNet Working Group., Leukemia, 26, 1730, 10.1038/leu.2012.30 Greenberg, 2011, Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) [abstract]., Leuk Res, 35, S6, 10.1016/S0145-2126(11)70016-9